Segment & Geographic Data
Quant-Grade Normalized Data
API & CSV Delivery
Acura Pharmaceuticals Inc's Business Segments
Acura Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Reportable Segments
-
Largest Segment
-
Total Revenue
-
Regions Reported
-
Annual Results
Revenue by Product & Service Category -
- Royalty0.1%
Revenue by Product & Service Category -
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Royalty | $ 0 | 0.1% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Acura Pharmaceuticals Inc
Acura Pharmaceuticals Inc. is a specialty pharmaceutical company that focuses on the research, development, and commercialization of innovative abuse-deterrent products. The company was founded in 1935 and is based in Palatine, Illinois, United States.
One of the primary goals of Acura Pharmaceuticals is to address the growing problem of prescription drug abuse. They aim to provide safer alternatives to existing opioid medications, which can potentially be abused or misused. The company's products utilize their proprietary technology, known as Aversion Technology, which is designed to deter abuse through various mechanisms.
Acura Pharmaceuticals has a diverse product portfolio that includes both prescription and over-the-counter medications. These products are targeted at a wide range of therapeutic areas, including pain management, cough and cold relief, allergy relief, and attention deficit hyperactivity disorder (ADHD) treatment.
The company's flagship product, Oxaydo (oxycodone HCl) tablets, is an immediate-release opioid analgesic that incorporates Aversion Technology. It is indicated for the management of acute and chronic moderate to severe pain. The abuse-deterrent properties of Oxaydo, such as physical barriers and chemical irritants, aim to prevent oral, intranasal, and intravenous abuse.
Acura Pharmaceuticals also has partnerships with other pharmaceutical companies and has licensed its Aversion Technology to them. These collaborations enable the development and commercialization of abuse-deterrent formulations of their partner's opioid products. This strategy helps the company to expand its reach in the market and maximize the potential impact of its technology.
In addition to their focus on abuse-deterrent products, Acura Pharmaceuticals also invests in research and development activities to expand their product pipeline. They aim to develop novel drug delivery technologies and formulations that enhance the safety, efficacy, and patient adherence of medications.
The company is dedicated to conducting rigorous clinical trials and obtaining regulatory approvals for their products. They work closely with regulatory authorities, such as the U.S. Food and Drug Administration (FDA), to ensure compliance with the necessary guidelines and regulations.
Acura Pharmaceuticals has a strong intellectual property portfolio, which includes patents and patent applications covering their proprietary technologies and formulations. These patents provide the company with a competitive advantage and help protect their innovations from potential infringement.
Overall, Acura Pharmaceuticals Inc. is a specialized pharmaceutical company that is committed to addressing the issue of prescription drug abuse through the development of abuse-deterrent products. Their innovative approach and strategic collaborations position them as a leader in this niche market, with the potential to make a significant impact on public health and safety.
One of the primary goals of Acura Pharmaceuticals is to address the growing problem of prescription drug abuse. They aim to provide safer alternatives to existing opioid medications, which can potentially be abused or misused. The company's products utilize their proprietary technology, known as Aversion Technology, which is designed to deter abuse through various mechanisms.
Acura Pharmaceuticals has a diverse product portfolio that includes both prescription and over-the-counter medications. These products are targeted at a wide range of therapeutic areas, including pain management, cough and cold relief, allergy relief, and attention deficit hyperactivity disorder (ADHD) treatment.
The company's flagship product, Oxaydo (oxycodone HCl) tablets, is an immediate-release opioid analgesic that incorporates Aversion Technology. It is indicated for the management of acute and chronic moderate to severe pain. The abuse-deterrent properties of Oxaydo, such as physical barriers and chemical irritants, aim to prevent oral, intranasal, and intravenous abuse.
Acura Pharmaceuticals also has partnerships with other pharmaceutical companies and has licensed its Aversion Technology to them. These collaborations enable the development and commercialization of abuse-deterrent formulations of their partner's opioid products. This strategy helps the company to expand its reach in the market and maximize the potential impact of its technology.
In addition to their focus on abuse-deterrent products, Acura Pharmaceuticals also invests in research and development activities to expand their product pipeline. They aim to develop novel drug delivery technologies and formulations that enhance the safety, efficacy, and patient adherence of medications.
The company is dedicated to conducting rigorous clinical trials and obtaining regulatory approvals for their products. They work closely with regulatory authorities, such as the U.S. Food and Drug Administration (FDA), to ensure compliance with the necessary guidelines and regulations.
Acura Pharmaceuticals has a strong intellectual property portfolio, which includes patents and patent applications covering their proprietary technologies and formulations. These patents provide the company with a competitive advantage and help protect their innovations from potential infringement.
Overall, Acura Pharmaceuticals Inc. is a specialized pharmaceutical company that is committed to addressing the issue of prescription drug abuse through the development of abuse-deterrent products. Their innovative approach and strategic collaborations position them as a leader in this niche market, with the potential to make a significant impact on public health and safety.
Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company that focuses on the development of innovative technologies for drug delivery and abuse deterrent formulations. The companys primary objective is to create products designed to mitigate the potential for misuse and abuse of medications, particularly those that have high potential for addiction. Below is an extensive overview of Acura Pharmaceuticals segments, products, and services.
Key Segments
1. Pharmaceutical Development:
- Acuras core segment revolves around the research and development of pharmaceutical products. This includes leveraging proprietary technologies to enhance the safety and efficacy of existing medications.
2. Abuse Deterrent Formulations:
- This segment focuses specifically on the development of medications that are engineered to be more difficult to misuse. By integrating abuse deterrent technologies, Acura aims to provide safer options for patients who require pain management and other treatments.
3. Commercialization:
- Once products are developed and approved, the company seeks collaborations or partnerships for the commercialization of its offerings, thereby expanding its market reach and ensuring wider accessibility of its technologies.
Products
1. AXS-05:
- AXS-05 is an investigational drug developed as a treatment for major depressive disorder and other neuropsychiatric conditions. It combines components with established mechanisms of action to provide therapeutic effects while aiming to minimize the potential for abuse.
2. Oxidized alpha-3 (D-Alpha-3-Alpha):
- This is a proprietary formulation that is considered for use in various therapeutic areas. The technology can alter the release of drugs in ways that could help reduce potential misuse while delivering therapeutic benefits.
3. Abuse-Deterrent Technologies:
- Acura has developed various technologies designed to prevent the abuse of drugs. These technologies can be applied to opioids and other medications that are commonly misused.
4. Partnership Products:
- Acura may also partner with other pharmaceutical companies to develop and market abuse-deterrent formulations, utilizing its proprietary technologies in conjunction with established medicinal compounds.
Services
1. Technology Licensing:
- Acura Pharmaceuticals offers licensing agreements for its proprietary drug delivery technologies. These agreements enable other companies to utilize Acuras innovations in their product development efforts.
2. Consulting and Support:
- The company may provide consulting services to other pharmaceutical firms seeking to develop abuse-deterrent products. This can include guidance on formulation technology and regulatory pathways.
3. Collaborative Research:
- Acura engages in collaborations with academic institutions and industry partners to advance research in drug delivery systems, especially focusing on abuse deterrent technologies.
4. Regulatory Expertise:
- Given the complexities involved in bringing pharmaceuticals to market, Acura offers expertise in regulatory affairs, assisting partners in navigating the approval processes required by regulatory bodies.
Conclusion
Acura Pharmaceuticals, Inc. is positioned to play a significant role in the pharmaceutical landscape by prioritizing safety and efficacy in the development of medications. Through its various segments, innovative products, and supportive services, the company addresses critical needs in pain management and associated fields while fostering a commitment to reducing the potential for drug abuse. Its focus on abuse deterrent formulations makes it a key player in addressing the ongoing issues related to prescription drug misuse and addiction.
Key Segments
1. Pharmaceutical Development:
- Acuras core segment revolves around the research and development of pharmaceutical products. This includes leveraging proprietary technologies to enhance the safety and efficacy of existing medications.
2. Abuse Deterrent Formulations:
- This segment focuses specifically on the development of medications that are engineered to be more difficult to misuse. By integrating abuse deterrent technologies, Acura aims to provide safer options for patients who require pain management and other treatments.
3. Commercialization:
- Once products are developed and approved, the company seeks collaborations or partnerships for the commercialization of its offerings, thereby expanding its market reach and ensuring wider accessibility of its technologies.
Products
1. AXS-05:
- AXS-05 is an investigational drug developed as a treatment for major depressive disorder and other neuropsychiatric conditions. It combines components with established mechanisms of action to provide therapeutic effects while aiming to minimize the potential for abuse.
2. Oxidized alpha-3 (D-Alpha-3-Alpha):
- This is a proprietary formulation that is considered for use in various therapeutic areas. The technology can alter the release of drugs in ways that could help reduce potential misuse while delivering therapeutic benefits.
3. Abuse-Deterrent Technologies:
- Acura has developed various technologies designed to prevent the abuse of drugs. These technologies can be applied to opioids and other medications that are commonly misused.
4. Partnership Products:
- Acura may also partner with other pharmaceutical companies to develop and market abuse-deterrent formulations, utilizing its proprietary technologies in conjunction with established medicinal compounds.
Services
1. Technology Licensing:
- Acura Pharmaceuticals offers licensing agreements for its proprietary drug delivery technologies. These agreements enable other companies to utilize Acuras innovations in their product development efforts.
2. Consulting and Support:
- The company may provide consulting services to other pharmaceutical firms seeking to develop abuse-deterrent products. This can include guidance on formulation technology and regulatory pathways.
3. Collaborative Research:
- Acura engages in collaborations with academic institutions and industry partners to advance research in drug delivery systems, especially focusing on abuse deterrent technologies.
4. Regulatory Expertise:
- Given the complexities involved in bringing pharmaceuticals to market, Acura offers expertise in regulatory affairs, assisting partners in navigating the approval processes required by regulatory bodies.
Conclusion
Acura Pharmaceuticals, Inc. is positioned to play a significant role in the pharmaceutical landscape by prioritizing safety and efficacy in the development of medications. Through its various segments, innovative products, and supportive services, the company addresses critical needs in pain management and associated fields while fostering a commitment to reducing the potential for drug abuse. Its focus on abuse deterrent formulations makes it a key player in addressing the ongoing issues related to prescription drug misuse and addiction.